Reversal of SARS-CoV2-Induced Hypoxia by Nebulized Sodium Ibuprofenate in a Compassionate Use Program
- Autores
- Salva, Oscar; Doreski, Pablo A.; Giler, Celia S.; Quinodoz, Dario C.; Guzmán, Lucia G.; Muñoz, Sonia Edith; Carrillo, Mariana Norma del Valle; Porta, Daniela Josefina; Ambasch, Germán; Coscia, Esteban; Tambini Diaz, Jorge L.; Bueno, Germán D.; Fandi, Jorge O.; Maldonado, Miriam A.; Peña Chiappero, Leandro E.; Fournier, Fernando; Pérez, Hernán A.; Quiroga, Mauro A.; Sala Mercado, Javier Agustin; Martínez Picco, Carlos; Beltrán, Marcelo Alejandro; Castillo Argañarás, Luis Fernando; Ríos, Nicolás Martínez; Kalayan, Galia I.; Beltramo, Dante Miguel; Garcia, Nestor Horacio
- Año de publicación
- 2021
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- Introduction: Sodium ibuprofenate in hypertonic saline (NaIHS) administered directly to the lungs by nebulization and inhalation has antibacterial and anti-inflammatory effects, with the potential to deliver these benefits to hypoxic patients. We describe a compassionate use program that offered this therapy to hospitalized COVID-19 patients. Methods: NaIHS (50 mg ibuprofen, tid) was provided in addition to standard of care (SOC) to hospitalized COVID-19 patients until oxygen saturation levels of > 94% were achieved on ambient air. Patients wore a containment hood to diminish aerosolization. Outcome data from participating patients treated at multiple hospitals in Argentina between April 4 and October 31, 2020, are summarized. Results were compared with a retrospective contemporaneous control (CC) group of hospitalized COVID-19 patients with SOC alone during the same time frame from a subset of participating hospitals from Córdoba and Buenos Aires. Results: The evolution of 383 patients treated with SOC + NaIHS [56 on mechanical ventilation (MV) at baseline] and 195 CC (21 on MV at baseline) are summarized. At baseline, NaIHS-treated patients had basal oxygen saturation of 90.7 ± 0.2% (74.3% were on supplemental oxygen at baseline) and a basal respiratory rate of 22.7 ± 0.3 breath/min. In the CC group, basal oxygen saturation was 92.6 ± 0.4% (52.1% were on oxygen supplementation at baseline) and respiratory rate was 19.3 ± 0.3 breath/min. Despite greater pulmonary compromise at baseline in the NaIHS-treated group, the length of treatment (LOT) was 9.1 ± 0.2 gs with an average length of stay (ALOS) of 11.5 ± 0.3 days, in comparison with an ALOS of 13.3 ± 0.9 days in the CC group. In patients on MV who received NaIHS, the ALOS was lower than in the CC group. In both NaIHS-treated groups, a rapid reversal of deterioration in oxygenation and NEWS2 scores was observed acutely after initiation of NaIHS therapy. No serious adverse events were considered related to ibuprofen therapy. Mortality was lower in both NaIHS groups compared with CC groups. Conclusions: Treatment of COVID-19 pneumonitis with inhalational nebulized NaIHS was associated with rapid improvement in hypoxia and vital signs, with no serious adverse events attributed to therapy. Nebulized NaIHS s worthy of further study in randomized, placebo-controlled trials (ClinicalTrials.gov: NCT04382768).
Fil: Salva, Oscar. Clínica Independencia; Argentina
Fil: Doreski, Pablo A.. Fundación Respirar; Argentina
Fil: Giler, Celia S.. Clínica Independencia; Argentina
Fil: Quinodoz, Dario C.. Sanatorio de la Cañada; Argentina
Fil: Guzmán, Lucia G.. Sanatorio de la Cañada; Argentina
Fil: Muñoz, Sonia Edith. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Investigaciones en Ciencias de la Salud. Universidad Nacional de Córdoba. Instituto de Investigaciones en Ciencias de la Salud; Argentina
Fil: Carrillo, Mariana Norma del Valle. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Investigaciones en Ciencias de la Salud. Universidad Nacional de Córdoba. Instituto de Investigaciones en Ciencias de la Salud; Argentina
Fil: Porta, Daniela Josefina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Investigaciones en Ciencias de la Salud. Universidad Nacional de Córdoba. Instituto de Investigaciones en Ciencias de la Salud; Argentina
Fil: Ambasch, Germán. Sanatorio Privado Mayo; Argentina
Fil: Coscia, Esteban. Sanatorio Privado Mayo; Argentina
Fil: Tambini Diaz, Jorge L.. Sanatorio Privado Mayo; Argentina
Fil: Bueno, Germán D.. Sanatorio Privado Mayo; Argentina
Fil: Fandi, Jorge O.. Clínica Independencia; Argentina
Fil: Maldonado, Miriam A.. Sanatorio San Roque; Argentina
Fil: Peña Chiappero, Leandro E.. Sanatori San Roque; Argentina
Fil: Fournier, Fernando. Clínica Francesa; Argentina
Fil: Pérez, Hernán A.. Sanatorio Alive; Argentina. University of Maryland; Estados Unidos
Fil: Quiroga, Mauro A.. Instituto Modelo de Cardiología; Argentina
Fil: Sala Mercado, Javier Agustin. Instituto Modelo de Cardiología; Argentina
Fil: Martínez Picco, Carlos. Clínica del Sol; Argentina
Fil: Beltrán, Marcelo Alejandro. Hospital Dr. Alberto Duhau; Argentina
Fil: Castillo Argañarás, Luis Fernando. Hospital Dr. Alberto Duhau; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Ríos, Nicolás Martínez. Quimica Luar Srl; Argentina
Fil: Kalayan, Galia I.. Provincia de Córdoba. Ministerio de Ciencia y Técnica. Centro de Excelencia en Productos y Procesos de Córdoba; Argentina
Fil: Beltramo, Dante Miguel. Provincia de Córdoba. Ministerio de Ciencia y Técnica. Centro de Excelencia en Productos y Procesos de Córdoba; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba; Argentina
Fil: Garcia, Nestor Horacio. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Investigaciones en Ciencias de la Salud. Universidad Nacional de Córdoba. Instituto de Investigaciones en Ciencias de la Salud; Argentina. Provincia de Córdoba. Ministerio de Ciencia y Técnica. Centro de Excelencia en Productos y Procesos de Córdoba; Argentina - Materia
-
ACUTE RESPIRATORY DISTRESS SYNDROME
CORONAVIRUS
COVID-19
HYPOXEMIA
SARS-COV-2
VIRAL PNEUMONIA - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
- Repositorio
.jpg)
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/151020
Ver los metadatos del registro completo
| id |
CONICETDig_86e232386c64e09b15a8649ccbd9a05c |
|---|---|
| oai_identifier_str |
oai:ri.conicet.gov.ar:11336/151020 |
| network_acronym_str |
CONICETDig |
| repository_id_str |
3498 |
| network_name_str |
CONICET Digital (CONICET) |
| spelling |
Reversal of SARS-CoV2-Induced Hypoxia by Nebulized Sodium Ibuprofenate in a Compassionate Use ProgramSalva, OscarDoreski, Pablo A.Giler, Celia S.Quinodoz, Dario C.Guzmán, Lucia G.Muñoz, Sonia EdithCarrillo, Mariana Norma del VallePorta, Daniela JosefinaAmbasch, GermánCoscia, EstebanTambini Diaz, Jorge L.Bueno, Germán D.Fandi, Jorge O.Maldonado, Miriam A.Peña Chiappero, Leandro E.Fournier, FernandoPérez, Hernán A.Quiroga, Mauro A.Sala Mercado, Javier AgustinMartínez Picco, CarlosBeltrán, Marcelo AlejandroCastillo Argañarás, Luis FernandoRíos, Nicolás MartínezKalayan, Galia I.Beltramo, Dante MiguelGarcia, Nestor HoracioACUTE RESPIRATORY DISTRESS SYNDROMECORONAVIRUSCOVID-19HYPOXEMIASARS-COV-2VIRAL PNEUMONIAhttps://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3Introduction: Sodium ibuprofenate in hypertonic saline (NaIHS) administered directly to the lungs by nebulization and inhalation has antibacterial and anti-inflammatory effects, with the potential to deliver these benefits to hypoxic patients. We describe a compassionate use program that offered this therapy to hospitalized COVID-19 patients. Methods: NaIHS (50 mg ibuprofen, tid) was provided in addition to standard of care (SOC) to hospitalized COVID-19 patients until oxygen saturation levels of > 94% were achieved on ambient air. Patients wore a containment hood to diminish aerosolization. Outcome data from participating patients treated at multiple hospitals in Argentina between April 4 and October 31, 2020, are summarized. Results were compared with a retrospective contemporaneous control (CC) group of hospitalized COVID-19 patients with SOC alone during the same time frame from a subset of participating hospitals from Córdoba and Buenos Aires. Results: The evolution of 383 patients treated with SOC + NaIHS [56 on mechanical ventilation (MV) at baseline] and 195 CC (21 on MV at baseline) are summarized. At baseline, NaIHS-treated patients had basal oxygen saturation of 90.7 ± 0.2% (74.3% were on supplemental oxygen at baseline) and a basal respiratory rate of 22.7 ± 0.3 breath/min. In the CC group, basal oxygen saturation was 92.6 ± 0.4% (52.1% were on oxygen supplementation at baseline) and respiratory rate was 19.3 ± 0.3 breath/min. Despite greater pulmonary compromise at baseline in the NaIHS-treated group, the length of treatment (LOT) was 9.1 ± 0.2 gs with an average length of stay (ALOS) of 11.5 ± 0.3 days, in comparison with an ALOS of 13.3 ± 0.9 days in the CC group. In patients on MV who received NaIHS, the ALOS was lower than in the CC group. In both NaIHS-treated groups, a rapid reversal of deterioration in oxygenation and NEWS2 scores was observed acutely after initiation of NaIHS therapy. No serious adverse events were considered related to ibuprofen therapy. Mortality was lower in both NaIHS groups compared with CC groups. Conclusions: Treatment of COVID-19 pneumonitis with inhalational nebulized NaIHS was associated with rapid improvement in hypoxia and vital signs, with no serious adverse events attributed to therapy. Nebulized NaIHS s worthy of further study in randomized, placebo-controlled trials (ClinicalTrials.gov: NCT04382768).Fil: Salva, Oscar. Clínica Independencia; ArgentinaFil: Doreski, Pablo A.. Fundación Respirar; ArgentinaFil: Giler, Celia S.. Clínica Independencia; ArgentinaFil: Quinodoz, Dario C.. Sanatorio de la Cañada; ArgentinaFil: Guzmán, Lucia G.. Sanatorio de la Cañada; ArgentinaFil: Muñoz, Sonia Edith. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Investigaciones en Ciencias de la Salud. Universidad Nacional de Córdoba. Instituto de Investigaciones en Ciencias de la Salud; ArgentinaFil: Carrillo, Mariana Norma del Valle. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Investigaciones en Ciencias de la Salud. Universidad Nacional de Córdoba. Instituto de Investigaciones en Ciencias de la Salud; ArgentinaFil: Porta, Daniela Josefina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Investigaciones en Ciencias de la Salud. Universidad Nacional de Córdoba. Instituto de Investigaciones en Ciencias de la Salud; ArgentinaFil: Ambasch, Germán. Sanatorio Privado Mayo; ArgentinaFil: Coscia, Esteban. Sanatorio Privado Mayo; ArgentinaFil: Tambini Diaz, Jorge L.. Sanatorio Privado Mayo; ArgentinaFil: Bueno, Germán D.. Sanatorio Privado Mayo; ArgentinaFil: Fandi, Jorge O.. Clínica Independencia; ArgentinaFil: Maldonado, Miriam A.. Sanatorio San Roque; ArgentinaFil: Peña Chiappero, Leandro E.. Sanatori San Roque; ArgentinaFil: Fournier, Fernando. Clínica Francesa; ArgentinaFil: Pérez, Hernán A.. Sanatorio Alive; Argentina. University of Maryland; Estados UnidosFil: Quiroga, Mauro A.. Instituto Modelo de Cardiología; ArgentinaFil: Sala Mercado, Javier Agustin. Instituto Modelo de Cardiología; ArgentinaFil: Martínez Picco, Carlos. Clínica del Sol; ArgentinaFil: Beltrán, Marcelo Alejandro. Hospital Dr. Alberto Duhau; ArgentinaFil: Castillo Argañarás, Luis Fernando. Hospital Dr. Alberto Duhau; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Ríos, Nicolás Martínez. Quimica Luar Srl; ArgentinaFil: Kalayan, Galia I.. Provincia de Córdoba. Ministerio de Ciencia y Técnica. Centro de Excelencia en Productos y Procesos de Córdoba; ArgentinaFil: Beltramo, Dante Miguel. Provincia de Córdoba. Ministerio de Ciencia y Técnica. Centro de Excelencia en Productos y Procesos de Córdoba; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba; ArgentinaFil: Garcia, Nestor Horacio. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Investigaciones en Ciencias de la Salud. Universidad Nacional de Córdoba. Instituto de Investigaciones en Ciencias de la Salud; Argentina. Provincia de Córdoba. Ministerio de Ciencia y Técnica. Centro de Excelencia en Productos y Procesos de Córdoba; ArgentinaSpringer Nature2021-08info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/151020Salva, Oscar; Doreski, Pablo A.; Giler, Celia S.; Quinodoz, Dario C.; Guzmán, Lucia G.; et al.; Reversal of SARS-CoV2-Induced Hypoxia by Nebulized Sodium Ibuprofenate in a Compassionate Use Program; Springer Nature; Infectious Diseases and Therapy; 10; 4; 8-2021; 2511-25242193-82292193-6382CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://link.springer.com/10.1007/s40121-021-00527-2info:eu-repo/semantics/altIdentifier/doi/10.1007/s40121-021-00527-2info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-10-22T11:45:44Zoai:ri.conicet.gov.ar:11336/151020instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-10-22 11:45:45.008CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
| dc.title.none.fl_str_mv |
Reversal of SARS-CoV2-Induced Hypoxia by Nebulized Sodium Ibuprofenate in a Compassionate Use Program |
| title |
Reversal of SARS-CoV2-Induced Hypoxia by Nebulized Sodium Ibuprofenate in a Compassionate Use Program |
| spellingShingle |
Reversal of SARS-CoV2-Induced Hypoxia by Nebulized Sodium Ibuprofenate in a Compassionate Use Program Salva, Oscar ACUTE RESPIRATORY DISTRESS SYNDROME CORONAVIRUS COVID-19 HYPOXEMIA SARS-COV-2 VIRAL PNEUMONIA |
| title_short |
Reversal of SARS-CoV2-Induced Hypoxia by Nebulized Sodium Ibuprofenate in a Compassionate Use Program |
| title_full |
Reversal of SARS-CoV2-Induced Hypoxia by Nebulized Sodium Ibuprofenate in a Compassionate Use Program |
| title_fullStr |
Reversal of SARS-CoV2-Induced Hypoxia by Nebulized Sodium Ibuprofenate in a Compassionate Use Program |
| title_full_unstemmed |
Reversal of SARS-CoV2-Induced Hypoxia by Nebulized Sodium Ibuprofenate in a Compassionate Use Program |
| title_sort |
Reversal of SARS-CoV2-Induced Hypoxia by Nebulized Sodium Ibuprofenate in a Compassionate Use Program |
| dc.creator.none.fl_str_mv |
Salva, Oscar Doreski, Pablo A. Giler, Celia S. Quinodoz, Dario C. Guzmán, Lucia G. Muñoz, Sonia Edith Carrillo, Mariana Norma del Valle Porta, Daniela Josefina Ambasch, Germán Coscia, Esteban Tambini Diaz, Jorge L. Bueno, Germán D. Fandi, Jorge O. Maldonado, Miriam A. Peña Chiappero, Leandro E. Fournier, Fernando Pérez, Hernán A. Quiroga, Mauro A. Sala Mercado, Javier Agustin Martínez Picco, Carlos Beltrán, Marcelo Alejandro Castillo Argañarás, Luis Fernando Ríos, Nicolás Martínez Kalayan, Galia I. Beltramo, Dante Miguel Garcia, Nestor Horacio |
| author |
Salva, Oscar |
| author_facet |
Salva, Oscar Doreski, Pablo A. Giler, Celia S. Quinodoz, Dario C. Guzmán, Lucia G. Muñoz, Sonia Edith Carrillo, Mariana Norma del Valle Porta, Daniela Josefina Ambasch, Germán Coscia, Esteban Tambini Diaz, Jorge L. Bueno, Germán D. Fandi, Jorge O. Maldonado, Miriam A. Peña Chiappero, Leandro E. Fournier, Fernando Pérez, Hernán A. Quiroga, Mauro A. Sala Mercado, Javier Agustin Martínez Picco, Carlos Beltrán, Marcelo Alejandro Castillo Argañarás, Luis Fernando Ríos, Nicolás Martínez Kalayan, Galia I. Beltramo, Dante Miguel Garcia, Nestor Horacio |
| author_role |
author |
| author2 |
Doreski, Pablo A. Giler, Celia S. Quinodoz, Dario C. Guzmán, Lucia G. Muñoz, Sonia Edith Carrillo, Mariana Norma del Valle Porta, Daniela Josefina Ambasch, Germán Coscia, Esteban Tambini Diaz, Jorge L. Bueno, Germán D. Fandi, Jorge O. Maldonado, Miriam A. Peña Chiappero, Leandro E. Fournier, Fernando Pérez, Hernán A. Quiroga, Mauro A. Sala Mercado, Javier Agustin Martínez Picco, Carlos Beltrán, Marcelo Alejandro Castillo Argañarás, Luis Fernando Ríos, Nicolás Martínez Kalayan, Galia I. Beltramo, Dante Miguel Garcia, Nestor Horacio |
| author2_role |
author author author author author author author author author author author author author author author author author author author author author author author author author |
| dc.subject.none.fl_str_mv |
ACUTE RESPIRATORY DISTRESS SYNDROME CORONAVIRUS COVID-19 HYPOXEMIA SARS-COV-2 VIRAL PNEUMONIA |
| topic |
ACUTE RESPIRATORY DISTRESS SYNDROME CORONAVIRUS COVID-19 HYPOXEMIA SARS-COV-2 VIRAL PNEUMONIA |
| purl_subject.fl_str_mv |
https://purl.org/becyt/ford/3.2 https://purl.org/becyt/ford/3 |
| dc.description.none.fl_txt_mv |
Introduction: Sodium ibuprofenate in hypertonic saline (NaIHS) administered directly to the lungs by nebulization and inhalation has antibacterial and anti-inflammatory effects, with the potential to deliver these benefits to hypoxic patients. We describe a compassionate use program that offered this therapy to hospitalized COVID-19 patients. Methods: NaIHS (50 mg ibuprofen, tid) was provided in addition to standard of care (SOC) to hospitalized COVID-19 patients until oxygen saturation levels of > 94% were achieved on ambient air. Patients wore a containment hood to diminish aerosolization. Outcome data from participating patients treated at multiple hospitals in Argentina between April 4 and October 31, 2020, are summarized. Results were compared with a retrospective contemporaneous control (CC) group of hospitalized COVID-19 patients with SOC alone during the same time frame from a subset of participating hospitals from Córdoba and Buenos Aires. Results: The evolution of 383 patients treated with SOC + NaIHS [56 on mechanical ventilation (MV) at baseline] and 195 CC (21 on MV at baseline) are summarized. At baseline, NaIHS-treated patients had basal oxygen saturation of 90.7 ± 0.2% (74.3% were on supplemental oxygen at baseline) and a basal respiratory rate of 22.7 ± 0.3 breath/min. In the CC group, basal oxygen saturation was 92.6 ± 0.4% (52.1% were on oxygen supplementation at baseline) and respiratory rate was 19.3 ± 0.3 breath/min. Despite greater pulmonary compromise at baseline in the NaIHS-treated group, the length of treatment (LOT) was 9.1 ± 0.2 gs with an average length of stay (ALOS) of 11.5 ± 0.3 days, in comparison with an ALOS of 13.3 ± 0.9 days in the CC group. In patients on MV who received NaIHS, the ALOS was lower than in the CC group. In both NaIHS-treated groups, a rapid reversal of deterioration in oxygenation and NEWS2 scores was observed acutely after initiation of NaIHS therapy. No serious adverse events were considered related to ibuprofen therapy. Mortality was lower in both NaIHS groups compared with CC groups. Conclusions: Treatment of COVID-19 pneumonitis with inhalational nebulized NaIHS was associated with rapid improvement in hypoxia and vital signs, with no serious adverse events attributed to therapy. Nebulized NaIHS s worthy of further study in randomized, placebo-controlled trials (ClinicalTrials.gov: NCT04382768). Fil: Salva, Oscar. Clínica Independencia; Argentina Fil: Doreski, Pablo A.. Fundación Respirar; Argentina Fil: Giler, Celia S.. Clínica Independencia; Argentina Fil: Quinodoz, Dario C.. Sanatorio de la Cañada; Argentina Fil: Guzmán, Lucia G.. Sanatorio de la Cañada; Argentina Fil: Muñoz, Sonia Edith. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Investigaciones en Ciencias de la Salud. Universidad Nacional de Córdoba. Instituto de Investigaciones en Ciencias de la Salud; Argentina Fil: Carrillo, Mariana Norma del Valle. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Investigaciones en Ciencias de la Salud. Universidad Nacional de Córdoba. Instituto de Investigaciones en Ciencias de la Salud; Argentina Fil: Porta, Daniela Josefina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Investigaciones en Ciencias de la Salud. Universidad Nacional de Córdoba. Instituto de Investigaciones en Ciencias de la Salud; Argentina Fil: Ambasch, Germán. Sanatorio Privado Mayo; Argentina Fil: Coscia, Esteban. Sanatorio Privado Mayo; Argentina Fil: Tambini Diaz, Jorge L.. Sanatorio Privado Mayo; Argentina Fil: Bueno, Germán D.. Sanatorio Privado Mayo; Argentina Fil: Fandi, Jorge O.. Clínica Independencia; Argentina Fil: Maldonado, Miriam A.. Sanatorio San Roque; Argentina Fil: Peña Chiappero, Leandro E.. Sanatori San Roque; Argentina Fil: Fournier, Fernando. Clínica Francesa; Argentina Fil: Pérez, Hernán A.. Sanatorio Alive; Argentina. University of Maryland; Estados Unidos Fil: Quiroga, Mauro A.. Instituto Modelo de Cardiología; Argentina Fil: Sala Mercado, Javier Agustin. Instituto Modelo de Cardiología; Argentina Fil: Martínez Picco, Carlos. Clínica del Sol; Argentina Fil: Beltrán, Marcelo Alejandro. Hospital Dr. Alberto Duhau; Argentina Fil: Castillo Argañarás, Luis Fernando. Hospital Dr. Alberto Duhau; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Ríos, Nicolás Martínez. Quimica Luar Srl; Argentina Fil: Kalayan, Galia I.. Provincia de Córdoba. Ministerio de Ciencia y Técnica. Centro de Excelencia en Productos y Procesos de Córdoba; Argentina Fil: Beltramo, Dante Miguel. Provincia de Córdoba. Ministerio de Ciencia y Técnica. Centro de Excelencia en Productos y Procesos de Córdoba; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba; Argentina Fil: Garcia, Nestor Horacio. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Investigaciones en Ciencias de la Salud. Universidad Nacional de Córdoba. Instituto de Investigaciones en Ciencias de la Salud; Argentina. Provincia de Córdoba. Ministerio de Ciencia y Técnica. Centro de Excelencia en Productos y Procesos de Córdoba; Argentina |
| description |
Introduction: Sodium ibuprofenate in hypertonic saline (NaIHS) administered directly to the lungs by nebulization and inhalation has antibacterial and anti-inflammatory effects, with the potential to deliver these benefits to hypoxic patients. We describe a compassionate use program that offered this therapy to hospitalized COVID-19 patients. Methods: NaIHS (50 mg ibuprofen, tid) was provided in addition to standard of care (SOC) to hospitalized COVID-19 patients until oxygen saturation levels of > 94% were achieved on ambient air. Patients wore a containment hood to diminish aerosolization. Outcome data from participating patients treated at multiple hospitals in Argentina between April 4 and October 31, 2020, are summarized. Results were compared with a retrospective contemporaneous control (CC) group of hospitalized COVID-19 patients with SOC alone during the same time frame from a subset of participating hospitals from Córdoba and Buenos Aires. Results: The evolution of 383 patients treated with SOC + NaIHS [56 on mechanical ventilation (MV) at baseline] and 195 CC (21 on MV at baseline) are summarized. At baseline, NaIHS-treated patients had basal oxygen saturation of 90.7 ± 0.2% (74.3% were on supplemental oxygen at baseline) and a basal respiratory rate of 22.7 ± 0.3 breath/min. In the CC group, basal oxygen saturation was 92.6 ± 0.4% (52.1% were on oxygen supplementation at baseline) and respiratory rate was 19.3 ± 0.3 breath/min. Despite greater pulmonary compromise at baseline in the NaIHS-treated group, the length of treatment (LOT) was 9.1 ± 0.2 gs with an average length of stay (ALOS) of 11.5 ± 0.3 days, in comparison with an ALOS of 13.3 ± 0.9 days in the CC group. In patients on MV who received NaIHS, the ALOS was lower than in the CC group. In both NaIHS-treated groups, a rapid reversal of deterioration in oxygenation and NEWS2 scores was observed acutely after initiation of NaIHS therapy. No serious adverse events were considered related to ibuprofen therapy. Mortality was lower in both NaIHS groups compared with CC groups. Conclusions: Treatment of COVID-19 pneumonitis with inhalational nebulized NaIHS was associated with rapid improvement in hypoxia and vital signs, with no serious adverse events attributed to therapy. Nebulized NaIHS s worthy of further study in randomized, placebo-controlled trials (ClinicalTrials.gov: NCT04382768). |
| publishDate |
2021 |
| dc.date.none.fl_str_mv |
2021-08 |
| dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/151020 Salva, Oscar; Doreski, Pablo A.; Giler, Celia S.; Quinodoz, Dario C.; Guzmán, Lucia G.; et al.; Reversal of SARS-CoV2-Induced Hypoxia by Nebulized Sodium Ibuprofenate in a Compassionate Use Program; Springer Nature; Infectious Diseases and Therapy; 10; 4; 8-2021; 2511-2524 2193-8229 2193-6382 CONICET Digital CONICET |
| url |
http://hdl.handle.net/11336/151020 |
| identifier_str_mv |
Salva, Oscar; Doreski, Pablo A.; Giler, Celia S.; Quinodoz, Dario C.; Guzmán, Lucia G.; et al.; Reversal of SARS-CoV2-Induced Hypoxia by Nebulized Sodium Ibuprofenate in a Compassionate Use Program; Springer Nature; Infectious Diseases and Therapy; 10; 4; 8-2021; 2511-2524 2193-8229 2193-6382 CONICET Digital CONICET |
| dc.language.none.fl_str_mv |
eng |
| language |
eng |
| dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/url/https://link.springer.com/10.1007/s40121-021-00527-2 info:eu-repo/semantics/altIdentifier/doi/10.1007/s40121-021-00527-2 |
| dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
| eu_rights_str_mv |
openAccess |
| rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
| dc.format.none.fl_str_mv |
application/pdf application/pdf |
| dc.publisher.none.fl_str_mv |
Springer Nature |
| publisher.none.fl_str_mv |
Springer Nature |
| dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
| reponame_str |
CONICET Digital (CONICET) |
| collection |
CONICET Digital (CONICET) |
| instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
| repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
| repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
| _version_ |
1846782155392286720 |
| score |
12.982451 |